JOURNAL OF INVASIVE CARDIOLOGY, a reputable publication by H M P COMMUNICATIONS, is dedicated to advancing the field of cardiology and cardiovascular medicine through rigorous research and scholarly discussion. With an ISSN of 1042-3931 and an E-ISSN of 1557-2501, this journal serves as a crucial resource for healthcare professionals, researchers, and students who seek to stay informed about the latest findings and innovations in invasive cardiology. Having achieved a 2023 Scopus rank of #185 out of 636 in General Medicine, placing it in the 70th percentile, the journal is recognized for its significant contributions to medical science, evidenced by its Q2 ranking in Radiology, Nuclear Medicine and Imaging, and Q3 status in both Cardiology and Cardiovascular Medicine. The journal has been in circulation since 1990 and continues to foster a platform for critical research in the United States, ensuring accessibility to vital information necessary for enhancing patient care and clinical practices within the domain of invasive procedures.

Minerva Cardiology and Angiology, published by EDIZIONI MINERVA MEDICA, is a prominent journal in the field of cardiology and cardiovascular medicine, with an ISSN of 2724-5683 and E-ISSN of 2724-5772. Established in 2021, this journal aims to foster the dissemination of cutting-edge research, clinical practice guidelines, and innovative methodologies relevant to cardiovascular health. As of 2023, it holds a commendable Q3 quartile rank in its category, reflecting its growing influence within the scientific community. The journal is indexed in Scopus, where it ranks #221 out of 387 in its field, placing it in the 43rd percentile overall. Although it currently does not offer Open Access options, articles published in Minerva Cardiology and Angiology contribute significantly to ongoing discussions and advancements in heart and vascular health. The journal serves as an invaluable resource for researchers, healthcare professionals, and students seeking to stay informed on the latest developments in cardiology.

Heart International is a prominent open-access journal dedicated to the fields of cardiology and cardiovascular medicine, published by TOUCH MEDICAL MEDIA LTD since 2006. Based in Italy, this journal serves as a vital platform for researchers, clinicians, and students, aiming to disseminate cutting-edge scientific findings and clinical insights that advance the understanding of heart health. With an ISSN of 2036-2579 and an emphasis on accessible content, Heart International ensures that valuable research is available to a wide audience, thereby contributing to the global discourse on cardiovascular issues. Although it currently holds a Q4 quartile ranking in its category and is positioned in the lower percentile for Scopus rankings, the journal is committed to improving its impact through rigorous peer review and high-quality publications. The journal covers a wide array of topics within the cardiology domain, making it an essential resource for those looking to stay abreast of the latest developments in heart research.

ACTA CARDIOLOGICA is a distinguished journal published by TAYLOR & FRANCIS LTD, focusing on the dynamic fields of Cardiology and Cardiovascular Medicine. Established in 1946, the journal has maintained a significant presence in the academic community, providing a platform for cutting-edge research and clinical studies that aim to address challenges in cardiovascular health. With its Q3 rating in both Cardiology and General Medicine categories, it showcases a robust compilation of articles that reflect the evolving landscape of cardiac care. Although ACTA CARDIOLOGICA is not an Open Access journal, it continues to serve a vital role for researchers, professionals, and students dedicated to advancing knowledge in cardiovascular health. This journal, with an ISSN of 0001-5385 and E-ISSN of 1784-973X, is a critical resource for those looking to stay updated on the latest developments and practices in the specialization, contributing significantly to the field until 2024 and beyond.

Kardiologie is an emerging journal dedicated to advancing the field of cardiology and cardiovascular medicine, published by SPRINGER HEIDELBERG in Germany. Established with the first issue in 2022, this journal provides a valuable platform for the dissemination of innovative research, clinical studies, and review articles that contribute to both theoretical knowledge and practical applications in cardiology. While the journal currently holds a Q4 category ranking in the field and occupies a percentile of 24 according to Scopus, it aims to enhance its impact factor by attracting high-quality submissions from researchers and clinicians alike. Kardiologie is particularly focused on bridging the gap between cutting-edge research and clinical practice, ensuring that the latest scientific findings are readily accessible to practitioners. Though it operates under traditional access options at present, the journal aspires to broaden its accessibility and reach in future editions, making it a pertinent choice for anyone interested in the evolving landscape of cardiovascular health.

Canadian Journal of Cardiology (ISSN: 0828-282X, E-ISSN: 1916-7075), published by Elsevier Science Inc, serves as a vital platform for disseminating high-quality research in the dynamic field of cardiology and cardiovascular medicine. Since its inception in 1985, this journal has established itself as a leader in the field, currently holding a prestigious Q1 ranking in Cardiology, indicating its significant impact and contribution to medical science. With a Scopus rank of #50 out of 387 in its category and placing in the 87th percentile, the journal showcases rigorous peer-reviewed articles that advance knowledge and practice in cardiology. Although the journal is not open access, it provides valuable insights and research findings that cater to clinicians, researchers, and students who are committed to improving cardiovascular health. As we approach the convergence of years to 2024, the Canadian Journal of Cardiology continues to strive for excellence, facilitating a discourse vital for both academic and clinical advancements in cardiology.

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

Journal of Cardiovascular Development and Disease, an esteemed publication by MDPI, has been a dedicated platform for disseminating cutting-edge research since its inception in 2014. Based in Switzerland, this Open Access journal not only provides unrestricted access to its content but also fosters global collaboration among scholars focusing on cardiovascular health and disease development. With an impressive focus classified as Q1 in Pharmacology, Toxicology and Pharmaceutics for 2023, it attracts a diverse range of interdisciplinary research, supporting advancements in pharmacological applications relevant to cardiac conditions. The journal's ongoing convergence through 2024 highlights its commitment to the evolving landscape of cardiovascular research, making it a vital resource for researchers, professionals, and students alike who are keen to contribute to and learn from significant developments in this critical field.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.